BUZZ-BioMarin rises after Q4 results beat estimates

Shares of drugmaker BioMarin Pharmaceutical BMRN.O rise 10.5% to $72.51 premarket

Co, after market close on Wednesday, reported Q4 rev. of $747 mln, beating estimate of $713.4 mln, as per data compiled by LSEG

Reported Q4 adj. profit of 92 cents per share vs estimate of 53 cents per share

Forecast 2025 adj. profit in the range of $4.20 to $4.40 per share, above estimate of $3.26 per share

Brokerage Evercore ISI says BMRN's Q4 results are "solid"; adds "it looks like investors may be willing to reward the company for solid execution after all. This was indeed an encouraging update on multiple fronts"

Stock had fallen 31.8% in 2024